Alkermes Plc. (ALKS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Richard F. Pops
Employees:
2,280
CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, IRELAND 00000
00-353-1-772-8000

Alkermes plc researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL, and VUMERITY. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate.

Data derived from most recent annual or quarterly report
Market Cap 4.997 Billion Shares Outstanding164.389 Million Avg 30-day Volume 1.003 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1
Price to Revenue4.152 Debt to Equity0.291 EBITDA-88.826 Million
Price to Book Value4.6279 Operating Margin-14.5581 Enterprise Value4.254 Billion
Current Ratio2.252 EPS Growth-1.632 Quick Ratio1.764
1 Yr BETA 0.4473 52-week High/Low 32.23 / 21.75 Profit Margin-14.6505
Operating Cash Flow Growth-113.0154 Altman Z-Score2.4596 Free Cash Flow to Firm -108.027 Million
Earnings Report2023-07-26
View SEC Filings from ALKS instead.

View recent insider trading info

Funds Holding ALKS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALKS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2023-06-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-26:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-25:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-06:
    Item 8.01: Other Events
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-15:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    71.2 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    67.2 Thousand total shares from 5 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LAURENCIN CATO T

    • Director
    7,479 2023-06-07 3

    NICHOLS CHRISTIAN TODD SVP, CHIEF COMMERCIAL OFFICER

    • Officer
    42,929 2023-06-05 5

    WYSENSKI NANCY

    • Director
    27,071 2023-05-09 3

    POPS RICHARD F DIRECTOR AND CEO, ALKERMES PLC

    • Officer
    • Director
    0 2023-02-23 2

    LANDINE MICHAEL J SVP, CORP DEV., ALKERMES, INC.

    • Officer
    250,442 2023-02-22 2

    BROWN IAIN MICHAEL SVP, CHIEF FINANCIAL OFFICER

    • Officer
    82,838 2023-02-22 2

    GAFFIN DAVID JOSEPH EVP, CLO, ALKERMES, INC.

    • Officer
    126,853 2023-02-22 3

    HOPKINSON CRAIG C. EVP R&D, CHIEF MEDICAL OFFICER

    • Officer
    56,559 2023-02-22 2

    JACKSON BLAIR CURTIS EVP, CHIEF OPERATING OFFICER

    • Officer
    114,117 2023-02-22 2

    MCKEON BRIAN P

    • Director
    25,169 2023-02-10 3

    DAGLIO DAVID ANGELO JR.

    • Director
    95,169 2023-02-10 4

    WILSON FRANK ANDERS

    • Director
    17,511 2022-07-07 2

    COOKE SHANE

    • Director
    17,511 2022-07-07 2

    SNYDERMAN NANCY LYNN MD

    • Director
    17,511 2022-07-07 2

    ALVA EMILY PETERSON

    • Director
    17,511 2022-07-07 3

    GAYNOR RICHARD

    • Director
    17,511 2022-07-07 2

    WRIGHT CHRISTOPHER I

    • Director
    17,511 2022-07-07 2

    ANSTICE DAVID W

    • Director
    84,905 2022-06-14 1

    DIXON WENDY L

    • Director
    53,124 2022-06-14 1

    BREYER ROBERT A

    • Director
    10,330 2021-05-20 0

    MITCHELL PAUL J

    • Director
    18,174 2021-05-20 0

    FRATES JAMES M SVP, ALKS INC; CFO ALKS

    • Officer
    247,497 2020-05-14 0

    BLOOM FLOYD E

    • Director
    0 2019-05-22 0

    ROBINSON JAMES A. JR. PRESIDENT & COO,ALKERMES, INC.

    • Officer
    4,412 2019-04-04 0

    BIBERSTEIN KATHRYN L EVP/CAO/CCO/CRO ALKS INC;

    • Officer
    182,073 2018-03-01 0

    STEJBACH MARK SVP/CHIEF COMM OFF, ALKS INC

    • Officer
    51,065 2018-03-01 0

    EHRICH ELLIOT EVP, R&D & CMO, ALKERMES, INC.

    • Officer
    57,056 2017-05-28 0

    PUGH GORDON G SVP, COO & CRO, ALKERMES, INC.

    • Officer
    No longer subject to file 2016-12-31 0

    PETERSON REBECCA SVP, CORPORATE COMMUNICATIONS

    • Officer
    2,644 2015-10-05 0

    HENWOOD GERALDINE

    • Director
    0 2014-05-28 0

    BOTKIN JAMES L SVP, ALKERMES GAINESVILLE LLC

    • Officer
    No longer subject to file 2013-12-31 0

    SKALETSKY MARK B

    • Director
    No longer subject to file 2013-11-13 0

    ELAN CORP PLC

    ELAN SCIENCE THREE LTD

    • 10% Owner
    No longer subject to file 2012-03-13 0

    RICH ALEXANDER

    • Director
    No longer subject to file 2011-09-16 0

    WALL MICHAEL A

    • Director
    No longer subject to file 2011-09-16 0

    BROECKER DAVID A PRESIDENT & CEO

    • Officer
    106,616 2009-06-16 0

    SCHIMMEL PAUL

    • Director
    360,600 2007-06-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    LAURENCIN CATO T - Director

    2023-06-07 17:12:25 -0400 2023-06-07 M 2,800 $22.97 a 10,279 direct yes

    LAURENCIN CATO T - Director

    2023-06-07 17:12:25 -0400 2023-06-07 S 2,800 $31.50 d 7,479 direct yes

    LAURENCIN CATO T - Director

    2023-06-07 17:12:25 -0400 2023-06-07 M 2,800 d 5,600 direct yes

    NICHOLS CHRISTIAN TODD - Officer SVP, CHIEF COMMERCIAL OFFICER

    2023-06-06 17:31:06 -0400 2023-06-05 F 1,555 $29.46 d 42,929 direct

    NICHOLS CHRISTIAN TODD - Officer SVP, CHIEF COMMERCIAL OFFICER

    2023-06-06 17:31:06 -0400 2023-06-05 M 3,500 a 44,484 direct

    NICHOLS CHRISTIAN TODD - Officer SVP, CHIEF COMMERCIAL OFFICER

    2023-06-06 17:31:06 -0400 2023-06-05 M 3,500 d 0 direct

    NICHOLS CHRISTIAN TODD - Officer SVP, CHIEF COMMERCIAL OFFICER

    2023-05-30 20:16:57 -0400 2023-05-30 M 19,634 $20.43 a 68,118 direct yes 1.2098 1.2098 2 0.0 1

    NICHOLS CHRISTIAN TODD - Officer SVP, CHIEF COMMERCIAL OFFICER

    2023-05-30 20:16:57 -0400 2023-05-30 M 19,634 d 44,327 direct yes

    NICHOLS CHRISTIAN TODD - Officer SVP, CHIEF COMMERCIAL OFFICER

    2023-05-30 20:16:57 -0400 2023-05-30 S 27,134 $28.93 d 40,984 direct yes 1.2098 1.2098 2 0.0 1

    WYSENSKI NANCY - Director

    2023-05-10 16:34:10 -0400 2023-05-09 M 6,250 $31.13 a 57,079 direct yes -0.0641 -3.2072 0.0 1 -3.2072 6

    WYSENSKI NANCY - Director

    2023-05-10 16:34:10 -0400 2023-05-09 M 6,250 d 0 direct yes

    WYSENSKI NANCY - Director

    2023-05-10 16:34:10 -0400 2023-05-09 M 35,000 $31.13 a 50,829 direct yes -0.0641 -3.2072 0.0 1 -3.2072 6

    WYSENSKI NANCY - Director

    2023-05-10 16:34:10 -0400 2023-05-09 M 35,000 d 0 direct yes

    WYSENSKI NANCY - Director

    2023-05-10 16:34:10 -0400 2023-05-09 S 41,250 $31.24 d 15,829 direct yes -0.0641 -3.2072 0.0 1 -3.2072 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALKERMES PLC ALKS 2023-06-07 22:15:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 21:45:05 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 21:15:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 20:45:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 20:15:06 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 19:45:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 19:15:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 18:45:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 18:15:03 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 17:45:05 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 17:15:04 UTC 4.6619 0.4081 4600000
    ALKERMES PLC ALKS 2023-06-07 16:45:03 UTC 4.6619 0.4081 4600000
    ALKERMES PLC ALKS 2023-06-07 16:15:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 15:45:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 15:15:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 14:45:04 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 14:15:03 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 13:45:03 UTC 4.6619 0.4081 4500000
    ALKERMES PLC ALKS 2023-06-07 13:15:04 UTC 4.6619 0.4081 4600000
    ALKERMES PLC ALKS 2023-06-07 12:45:04 UTC 4.6619 0.4081 4600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AGF Investments Trust- AGFIQ U.S. Market Neutral Momentum Fund ALKS -1284.0 shares, $-25615.8 2020-12-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund ALKS -278.0 shares, $-4606.46 2020-09-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund ALKS -2332.0 shares, $-60935.16 2022-12-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments